What were Piramal Pharma Ltd's latest quarterly results?
Piramal Pharma Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -3500.0%
- Revenue Growth YoY: -2.9%
- Operating Margin: 9.0%
Piramal Pharma Ltd: Stock Analysis & Fundamentals
Updated this weekPiramal Pharma Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. ROE: 1.1%. This stock is not currently in the Nifty 500 momentum outperformers list.
What's Happening
🌐FII stake decreased 1.5% this quarter
🏛️DII accumulation — stake up 1.1%
Key Numbers
Current Price
₹144
Dividend Yield
0.10%
Market Cap
19.1K Cr
Valuation
N/AOther Top Pharma - API & CRAMS Stocks Beating Nifty 500
Frequently Asked Questions: Piramal Pharma Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Piramal Pharma Ltd's price-to-book ratio?
Piramal Pharma Ltd's price-to-book ratio is 2.4x.
- Price-to-Book (P/B): 2.4x
- Book Value per Share: ₹61
- Current Price: ₹144
Is Piramal Pharma Ltd a fundamentally strong company?
Piramal Pharma Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 6.0%
Is Piramal Pharma Ltd debt free?
Piramal Pharma Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹5,000 Cr
What is Piramal Pharma Ltd's return on equity (ROE) and ROCE?
Piramal Pharma Ltd's return ratios over recent years
- FY2023: ROCE 2.0%
- FY2024: ROCE 5.0%
- FY2025: ROCE 6.0%
Is Piramal Pharma Ltd's cash flow positive?
Piramal Pharma Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹892 Cr
- Free Cash Flow (FCF): ₹404 Cr
- CFO/PAT Ratio: 980% (strong cash conversion)
What is Piramal Pharma Ltd's dividend yield?
Piramal Pharma Ltd's current dividend yield is 0.10%.
- Dividend Yield: 0.10%
- Current Price: ₹144
Who holds Piramal Pharma Ltd shares — promoters, FII, DII?
Piramal Pharma Ltd's shareholding pattern (Dec 2025)
- Promoters: 34.9%
- FII (Foreign): 29.7%
- DII (Domestic): 15.7%
- Public: 19.4%
Is promoter holding increasing or decreasing in Piramal Pharma Ltd?
Piramal Pharma Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 34.9% (Dec 2025)
- Previous Quarter: 34.9% (Sep 2025)
- Change: 0.00% (stable)
Is Piramal Pharma Ltd a new momentum entry or an established outperformer?
Piramal Pharma Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Piramal Pharma Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Piramal Pharma Ltd may be worth studying
- Cash flow is positive — CFO ₹892 Cr
What is the investment thesis for Piramal Pharma Ltd?
Piramal Pharma Ltd investment thesis summary:
What is the future outlook for Piramal Pharma Ltd?
Piramal Pharma Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.